Eligible patients undergoing hyperthermic intraperitoneal perfusion therapy were enrolled as research subjects
Conditions
Interventions
Group A (experimental) :Standard analgesic therapy combined with traditional chinese medicine acupoint application at Shenque, Zhongwan, Zusanli, and Ashi points.
Group B (control):A placebo patch with conventional analgesic treatment at Shenque, Zhongwan, Zusanli, and Ashi points.
Sponsors
Jinan Third People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) patients aged 18-80 years, with malignant tumors confirmed pathologically, or postoperative patients with definitive pathological diagnosis, in accordance with National Comprehensive Cancer Network (NCCN) or Chinese Society of Clinical Oncology (CSCO) guidelines recommending HIP therapy, with complete clinical data available; (2) adequate bone marrow, hepatic, cardiac, renal, and coagulation function; (3) absence of clinically significant comorbidities; (4) expected survival of more than 3 months; (5) voluntary participation with signed informed consent.
Exclusion criteria
Exclusion criteria: (1) absence of definitive pathological diagnosis; (2) severe pelvic-abdominal adhesions, intestinal obstruction, gastrointestinal diseases, or acute or chronic intra-abdominal infections prior to HIP; (3) severe cardiac, hepatic, pulmonary, renal, or cerebral dysfunction; (4) bleeding tendency; (5) contraindications to HIP or surgery; (6) thermoregulatory or sensory disorders; (7) inability to communicate normally; (8) irregular treatment or incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain evaluation:Visual analogue scales;Quality of life assessment: Karnofsky Performance Status scale; | — |
Countries
China
Contacts
Public ContactChunhui Lu
Jinan Third People's Hospital
Outcome results
None listed